MedTrace Logo

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

NCT04479579 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2022-04-22

No results posted yet for this study

Summary

This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer. This study is designed to evaluate the adherence to extended deep vein thrombosis prophylaxis (DVT) with the direct oral anticoagulant apixaban on the background of historical data from the investigator's center on low-molecular-weight heparin (LMWH) substandard adherence in the same setting.

Conditions

  • Neoplasms Malignant
  • Surgery
  • Venous Thromboembolism
  • Prophylaxis
  • Adherence, Medication

Interventions

DRUG

Apixaban 2.5 milligram

apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day

Sponsors & Collaborators

Principal Investigators

  • Sam Schulman, MD, PhD · Dr.

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2021-10-31
Completion
2021-11-06
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04479579 on ClinicalTrials.gov